Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul J Tacken

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Immunology|March 25, 2006
Monocyte CD64 or CD89 targeting by surfactant protein D/anti-Fc receptor mediates bacterial uptakePaul J Tacken, Joseph J Batenburg
Seminars in Immunology|January 29, 2011
Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccinesPaul J Tacken, Carl G Figdor
Blood|February 8, 2013
Targeting dendritic cells--why bother?Martin Kreutz, Paul J Tacken, Carl G Figdor
Immunobiology|August 22, 2006
Targeting antigens to dendritic cells in vivoPaul J Tacken, Ruurd Torensma, Carl G Figdor
Biomaterials|July 5, 2011
The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cellsLuis J Cruz, Paul J Tacken, Remco Fokkink, et al.
European Journal of Immunology|June 2, 2012
Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor traffickingPaul J Tacken, Menno Ter Huurne, Ruurd Torensma, et al.
Nature Reviews. Immunology|September 15, 2007
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targetingPaul J Tacken, I Jolanda M de Vries, Ruurd Torensma, et al.
Nanomedicine (London, England)|February 10, 2017
Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicityLuis J Cruz, Paul J Tacken, Christina Eich, et al.
Methods in Enzymology|May 10, 2012
Targeting nanoparticles to dendritic cells for immunotherapyLuis J Cruz, Paul J Tacken, Felix Rueda, et al.
Biomaterials|March 14, 2012
Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGNLuis J Cruz, Paul J Tacken, Jeanette M Pots, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Immunology|March 25, 2006
Monocyte CD64 or CD89 targeting by surfactant protein D/anti-Fc receptor mediates bacterial uptakePaul J Tacken, Joseph J Batenburg
Seminars in Immunology|January 29, 2011
Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccinesPaul J Tacken, Carl G Figdor
Blood|February 8, 2013
Targeting dendritic cells--why bother?Martin Kreutz, Paul J Tacken, Carl G Figdor
Immunobiology|August 22, 2006
Targeting antigens to dendritic cells in vivoPaul J Tacken, Ruurd Torensma, Carl G Figdor
Biomaterials|July 5, 2011
The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cellsLuis J Cruz, Paul J Tacken, Remco Fokkink, et al.
European Journal of Immunology|June 2, 2012
Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor traffickingPaul J Tacken, Menno Ter Huurne, Ruurd Torensma, et al.
Nature Reviews. Immunology|September 15, 2007
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targetingPaul J Tacken, I Jolanda M de Vries, Ruurd Torensma, et al.
Nanomedicine (London, England)|February 10, 2017
Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicityLuis J Cruz, Paul J Tacken, Christina Eich, et al.
Methods in Enzymology|May 10, 2012
Targeting nanoparticles to dendritic cells for immunotherapyLuis J Cruz, Paul J Tacken, Felix Rueda, et al.
Biomaterials|March 14, 2012
Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGNLuis J Cruz, Paul J Tacken, Jeanette M Pots, et al.
Pageof 3